AI
PCRX icon

Axiom Investors’s Pacira BioSciences PCRX Stock Holding History

Axiom Investors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,691
Closed -$627K – 149
2017
Q3 		$627K Sell
16,691
-19,733
-54% -$794K 0.01% 132
2017
Q2 		$1.74M Buy
36,424
+5,988
+20% +$278K 0.04% 125
2017
Q1 		$1.39M Buy
+30,436
New +$1.32M 0.04% 140
2015
Q1 		– Sell
-17,390
Closed -$1.54M – 156
2014
Q4 		$1.54M Sell
17,390
-8,084
-32% -$765K 0.04% 125
2014
Q3 		$2.47M Sell
25,474
-2,826
-10% -$275K 0.06% 101
2014
Q2 		$2.6M Buy
28,300
+19,770
+232% +$1.51M 0.06% 94
2014
Q1 		$597K Buy
+8,530
New +$580K 0.01% 146

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Axiom Investors's PCRX Position: Q4 2017 in Review

Axiom Investors sold out of Pacira BioSciences (PCRX) in Q4 2017, closing a stake of 16,691 shares — an estimated $627K sold.

Axiom Investors first reported a position in PCRX in Q1 2014 and held it in 7 quarters. The position peaked at $2.6M in Q2 2014. 185 funds tracked by Wall St. Rank hold PCRX as of Q4 2017.

  • Axiom Investors reported no remaining Pacira BioSciences position as of Q4 2017 after selling out during the quarter.
  • Axiom Investors sold 16,691 Pacira BioSciences shares in Q4 2017, an estimated $627K.
  • Axiom Investors first reported a position in Pacira BioSciences in Q1 2014 and held it in 7 quarters.
  • Axiom Investors's Pacira BioSciences position peaked at $2.6M in Q2 2014.
  • 185 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2017.

Based on Axiom Investors's 13F filing for Q4 2017, filed 14 Feb 2018.